**Trigger Warning**
Naman Julka-Anderson and Jo McNamara catch up with Dr. Clive Peedell as part of our paid series with Boston Scientific where Clive talks about his career, talks about his experience and experience of SpacerOAR™.
To use this podcast as CPD, look at these reflection points:
1) read Clive’s research: SpaceOAR™ hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review.
2) reflect on the benefits of shorter radiotherapy fractionations.
Links from podcast:
Please like and subscribe to Rad Chat on your podcast library.
Our links:
Boston Scientific Disclaimer:
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at
www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
Clive Peedell was compensated by Boston Scientific for their contribution to this presentation.
This podcast is sponsored by Boston Scientific.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
This material is intended to discuss common clinical considerations and procedural steps for the use of the reference technology but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician’s professional judgement in consideration of all available information for the individual case.
Products discussed are for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.
SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue Hydrogels contain Polyethylene Glycol (PEG). SpaceOAR Vue Hydrogel contains iodine. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention.
2024 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. (Clive Peedell: URO-1996207-AA) (Sept 2024)